Alzheimer's Disease Clinical Trials in New York

Showing 161-180 of 291 trials

First in Human Study for Safety and Tolerability of AL003.

NCT03822208

This is a multi-center, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease. The study is designed to systematically assess the safety (including immunogenicity) and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL003.

HealthyAlzheimer Disease

Alector Inc.54 participantsStarted Mar 2019

Delray Beach, Florida, United States • Lady Lake, Florida, United States • Orlando, Florida, United States +3 more locations

TERMINATEDPhase 3< 1 mile

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

NCT02477800

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) \[ADAS-Cog 13\], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) \[ADCS-ADL-MCI\].

Alzheimer's Disease

Biogen1,653 participantsStarted Aug 2015

Phoenix, Arizona, United States • Tucson, Arizona, United States • Fullerton, California, United States +178 more locations

First in Human Study for Safety and Tolerability of AL003.

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Alzheimer's Disease Trials in Other Cities

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

Orexin and Tau Pathology in Cognitively Normal Elderly

Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients

A Phase I Study for Safety and Tolerability of AL002.

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

Aricept to Improve Functional Tasks in Vascular Dementia

To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

Randomized Evaluation of Default Access to Palliative Services

Clinical Evaluation of Flortaucipir F 18

A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects

18F-AV-1451 Autopsy Study

Cholinesterase Inhibitor Discontinuation

Other Conditions in New York